Avid Bioservices Inc (CDMO)

[2ndstr2thert]

For those who do not know PPHM owns shares in a Chinese company
that is and has been treating patients in China with one of our TNT products ( VIVATUXIN - TNT 3 AND I131 )and LYM 1.
Anyone have any idea how much these shares are currently worth in USA dollars ?


Peregrine Pharmaceuticals, Inc. (the “Company”) entered into a Settlement Agreement and Mutual General Release dated June 4, 2009 (the “Settlement Agreement”) with Cancer Therapeutics Laboratories (“CTL”), Alan Epstein, M.D. (“Dr. Epstein”), Clive Taylor, M.D. and Peisheng Hu, M.D. (collectively, the “CTL Parties”), providing for a settlement and release of all claims with respect to our previously disclosed litigation with the CTL Parties. The dismissal of claims was filed in the Superior Court of the State of California for the County of Orange on June 18, 2009. Medibiotech Co., Inc. (“Medibiotech”) and Shanghai Medipharm Biotech Co., Ltd. were once parties to the litigation but previously settled with us.

Under the Settlement Agreement, we agreed to dismiss with prejudice our claims for breach of contract and interference with contractual relations, as well as all other causes of action, stemming from our 1995 license agreement, as amended, with CTL. CTL agreed to dismiss its breach of contract counterclaim, as well as all other causes of action. In connection with the Settlement Agreement, (1) the Company agreed to pay to CTL the sum of four hundred thousand dollars ($400,000) in eight equal monthly installments of fifty thousand dollars ($50,000) commencing upon execution of the Settlement Agreement and continuing on the first business day of each succeeding month until paid in full, (2) CTL agreed to cause to be issued to the Company 950,000 shares of Medibiotech (which represents fifty percent (50%) of the shares of Medibiotech owned by CTL), and (3) the Company and Dr. Epstein entered into a license agreement, effective as of September 20, 1995, pursuant to which Dr. Epstein granted to the Company (i) a fully paid-up, royalty free, exclusive worldwide license to the murine clone TNT1 and (ii) a fully paid-up, royalty free, non-exclusive worldwide (except in the Peoples Republic of China) license to the murine clones TNT2 and TNT3. The foregoing license grants include our right to grant sublicenses, to make, have made, modify, have modified, use, sell and offer for sale, murine clone TNT1, TNT2 and TNT3 products and derivatives thereof, but not to sell the murine clones. We also granted back to Dr. Epstein a limited, fully paid-up, royalty free, exclusive license to the murine clone TNT1, with the right to grant sublicenses, to make, have made, modify, have modified, offer to sell, sell and use the murine clone TNT1 and its products solely in the Peoples Republic of China effective as of August 29, 2001. In consideration for the foregoing license grants, we paid Dr. Epstein the sum of one thousand dollars ($1,000), which amount was deducted from the initial $50,000 payment.

The Settlement Agreement contains a full general release between the Company and the CTL Parties of all action or actions, causes of action, in law or in equity, suits, debts, liens, contracts agreements, promises, liability, claims, demands, damages, loss, cost or expense, of any nature whatsoever, known or unknown, fixed or contingent, by reason of any act, omission, cause, matter or thing whatsoever from the beginning of time.

Information contained herein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


PEREGRINE PHARMACEUTICALS, INC.




Date: June 19, 2009

By:
/s/ Paul J. Lytle
Paul J. Lytle
Chief Financial Officer

-------------------------------------------------------------------


I took this post from Terry D ( Silicon Investor ) .


Medipharm seems to be doing Okay. Looks like LYM-1 (AKA Oncolym) is still a go for Medipharm. They also have the TNT fusion protein technology licensed from USC. I wonder just how much of the TNT technology Peregrine still controls or if we get any royalties from the part Medipharm has.

Shanghai MediPharm Biotech is a wholly-owned subsidiary of Medipharm Biotech Biopharmaceutical Ltd (Bermuda) focused on becoming China’s leading oncology biopharma by providing novel, antibody-based, targeted radio immunotherapy for malig-nant cancers. Following 15 years of R&D in antibody related biopharmaceuticals, the company has a strong intellectual prop-erty portfolio, including Vivatuxin®, a chimeric tumor necrosis therapy approved by China’s State Food and Drug Administra-tion for lung cancer and launched in 2007, as well as other can-didates in radio immunotherapy. Through a strategic marketing collaboration study with the Ministry of Health of China currently covering 101 hospitals, the company has agreements to supply 20,000 doses of Vivatuxin®, priced at $3,000 each, used for the treatment of advanced lung cancer patients, who have previ-ously failed at least one course of chemotherapy, and is negotating collaboration with additional 50 hospitals. Furthermore, as the first radio immunotherapy for solid tumors in the world and a potential therapy for all malignant solid tumors,
Vivatuxin® is undergoing Phase III clinical study registrations for glioma and liver cancer, as well as preclinical trials for colorectal and breast cancers.
Finally, the company has two exclusive licenses in radio immunotherapy technology platforms from University of Southern California Cancer Therapeutic Lab, namely Lym-1 for non-Hodgkin lymphoma, which started Phase I clinical trials in 2010, and TNT fusion protein technology for solid tumors. Currently, MediPharm has a staff of 53 professionals, and with 105,000 square feet GMP-approved world class manufacturing facilities, which include a 500L B. Braun bioreactor, the company has the capacity to produce 100,000 drug doses per year.

http://www.wallstreetresearch.org/

--------------------------------------------------------------


SiliconInvestor
Advanced Search [ sign in ]

register
An important announcement for Silicon Investor members and an introduction from Craig Longhurst

Biotech / Medical : Peregrine Pharmaceuticals, Inc.( PPHM)
Public Reply | Prvt Reply | Mark as Last Read | File Previous 10 | Next 10 | Previous | Next
To: Terry D. who started this subject 1/18/2004 5:25:22 PM
From: cjgaddy of 3711

CHINA TNT Refresher: Interim Lung Results 6-2002

6-19-2002: “INNOVATIVE ADMINISTRATION OF RADIOLABELED TNT SUCCESSFULLY TREATS INOPERABLE LUNG CANCER
TNT Data Presented at Society of Nuclear Medicine’s 49th Annual Meeting”
http://www.peregrineinc.com/prelease.asp?id=6190271436

June 19, 2002 - Peregrine Pharmaceuticals Inc. announced today detailed results from clinical research conducted in China that show 56% efficacy was achieved when patients with inoperable lung cancer were treated with the company's 131iodine labeled chimeric TNT (131I-chTNT) antibody drug using an innovative method of intratumoral injection. Patients treated by this method had a disease control rate of 100%, demonstrating 131I-chTNT can achieve significant therapeutic effects in late stage lung cancer. The results provide substantial validation of Peregrine's proprietary TNT technology, which is a radiolabeled monoclonal antibody that targets the necrotic core of solid tumors. The interim lung cancer data were presented at the Society of Nuclear Medicine's 49th Annual Meeting in Los Angeles. The study was independently designed and conducted by researchers at the Shanghai Tumor Hospital.

The Phase I/II study compared the efficacy of three different methods of administration of 131I-chTNT for patients with inoperable late stage lung cancer: intravenous, intratumoral, and a combination of intravenous plus intratumoral injection. The results demonstrated that the method of intratumoral injection alone achieved a 56% complete and partial tumor remission rate. The combined intravenous plus intratumoral injection method achieved 40% and the intravenous method alone achieved 9% tumor remission rate. The disease control rate for all three methods of treatment, including complete and partial remission and stable disease, was 88% for the 43 patients assessed in the study. The highest therapeutic effect was obtained by using common bronchoscopy and computer tomography (CT) scan instruments in a new technique to directly infuse the tumor with lethal doses of 131I-chTNT.

"Peregrine is reviewing the intratumoral injection techniques used to maximize delivery of radiolabeled TNT to the tumor while minimizing healthy tissue exposure. This will assist us in designing a lung cancer study in the USA," said Edward Legere, CEO of Peregrine Pharmaceuticals. "By using standardized equipment that is routinely used at medical centers around the world, it is possible the treatment could be widely adopted by oncologists treating late stage lung cancer patients."

"This data highlights the promise of TNT for the treatment of late stage lung cancer," said Alan L. Epstein, M.D., Ph.D., co-author of the lung cancer research, inventor of the TNT technology, and Peregrine's scientific consultant. "In this study, intratumoral injection caused substantially higher complete and partial remission rates than the other methods of administration. Given there are no effective treatments for inoperable late stage lung cancer, there is a significant unmet need for new therapies. Directly infusing the drug into the tumor mass may also reduce the systemic toxicity often seen with intravenous administration of radionuclides."

With a population of approximately 1.3 billion, China is a vast market for cancer therapy. Cancer became the main cause of death in China in 1996, with over 7.3 million new cases and just over 3 million deaths annually from cancer in China. The explosion in the number of cases of lung, breast, colon and rectal cancer was caused partly by the aging of China's population. In the USA, there were approximately 170,000 new cases of lung cancer in 1999, making it the most common cancer in the Western world. According to the American Cancer Society and the World Health Organization, since the mid-1990s, about 150,000 Americans have died each year from the disease. Lung cancer is the leading category of cancer death in men, and - since the late 1980s - it has surpassed breast cancer as the leading category of cancer death in women.

Summary of Clinical Study for Lung Cancer:

The poster summarizing the unaudited results of this Phase I/II study can be accessed on Peregrine's web site at:
http://www.peregrineinc.com/Technology.asp?id=Posters+and+Abstracts
As previously announced, a total of 43 patients enrolled in this study had a cytological and histological confirmed diagnosis of stage IIIb (30/43) or IV (13/43) inoperable lung cancer. As confirmed by fine needle biopsy, 24 patients (56%) had a diagnosis of adenocarcinoma, 12 patients (28%) were diagnosed with squamous carcinoma, six patients (14%) with small-cell lung cancer, and one patient (2%) with adeno-squamous carcinoma.

22 patients in the first group were administrated 131I-chTNT by intravenous drug infusion, 16 patients in the second group were administrated by intratumoral injection, and five patients in the third group received both treatments. The dose for each patient was 0.8 mCi/kg, which was repeated two weeks later. Patients receiving intravenous administration were given a total dose of 131I-chTNT delivered in 250 ml of normal saline through a free-flowing intravenous line. For the second group, the intratumoral injection of TNT was directed by thoracic CT guided catheter using a multiple-hole needle. The CT images clearly showed tumor localization, the needle pathway, and the site of administration. In the third group, 75% dosage was given by intratumoral injections and 25% by intravenous infusion.

Partial remission (PR) was defined as a greater than 50% reduction in tumor mass in all lesions and complete remission (CR) as no detectable tumor for greater than 10 weeks. Patients receiving intravenous injection alone had two PR (9%), 16 had stable disease (73%), and four progressed (18%). Those receiving intratumoral injection had one CR (6%), 8 PR (50%), seven had stable disease (44%), and zero progressed. Finally, those in the third group had one CR (20%), one PR (20%), two had stable disease (40%), and one progressed (20%). Toxicity was limited to mild and reversible bone marrow suppression in 20 cases.

Report TOU Violation
Public Reply | Prvt Reply | Mark as Last Read | File Previous 10 | Next 10 | Previous | Next
Home Mail Hot SubjectMarks PeopleMarks Keepers Settings
Terms Of Use Contact Us Copyright/IP Policy Privacy Policy About Us FAQ
Copyright © 1995-2013 Knight Sac Media. All rights reserved.

--------------------------------------------------------------------